[Pharmacokinetics and clinical experience with amikacin. A new aminoglycoside antibiotic].
The pharmacokinetic data of amikacin were determined after a 1 hr constant infusion with a dosage of 7.5 mg/kg body weight in 12 healthy test subjects. Microbiological bioassay was performed by the agar diffusion test. After the infusion, the mean amikacin serum concentration was 37.5 mug/ml and, 8 hours later, decreased to an average of 1.3 mug/ml. The biological half-life amounted to a mean of 114.2 min, the area below the concentration-time-curve was calculated to an average of 140.4 hr - mug/ml. The renal clearance of amikacin was determined during a 4 hr constant infusion in 3 test individuals; the average clearance was 84.3 ml/min - 1.73 m2. 38 patients with severe bronchopulmonary, urinary and peritoneal infections were treated with an average daily dose of 10-15 mg of amikacin per kg body weight during a mean period of 10 days. 32 patients showed clinical improvement, 17 of them with complete elimination of the pathogenic bacteria.
D000328:Adult; D000368:Aged; D000583:Amikacin / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D000617:Aminoglycosides / Q000627:therapeutic use; D001682:Biological Availability; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007612:Kanamycin / Q000031:analogs & derivatives*; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D010538:Peritonitis / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy
D000617:Aminoglycosides; D007612:Kanamycin; D000583:Amikacin
Pharmakokinetik und klinische Erfahrungen mit Amikacin. Ein neues Aminoglykosid-Antibiotikum